Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Alteogen Submits Application for Biosimilar Aflibercept in Korea

Sep 13, 2024

On 13 September 2024, Korea Biomedical Review reported that Korea-based Alteogen has submitted a domestic marketing authorisation application for its ALT-L9, biosimilar to Regeneron’s Eylea® (aflibercept), for treatment of nAMD.

This follows Alteogen’s subsidiary, Altos Biologics’, MAA submission to the EMA in July 2024 for ALT-L9, with marketing approval expected in 2025.  Altos Biologics completed enrolment in its phase 3 trials of ALT-L9 in patients with nAMD in February 2023.  The trials reportedly demonstrated therapeutic equivalence between ALT-L9 and Eylea®.

The first aflibercept biosimilar approved in Korea was Samsung Bioepis’ Afilivu® in February 2024, which is being marketed by Samil Pharmaceutical.  Celltrion’s Eydenzelt™  (CT-P42) (aflibercept) received Korean approval in May 2024.